Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine
Status:
Completed
Trial end date:
2017-02-24
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the best dosing schedule of a combined
treatment of PEG Intron® (pegylated Interferon-alfa 2b) plus a peptide vaccine (gp100) that
may help improve immune response in patients that had Stage II or Stage III melanoma and are
free of the disease. The safety and tolerability of this drug combination will also be
studied. Researchers also want to collect long-term follow-up information.